Comparison of epoetin alfa and darbepoetin alfa doses routinely used in clinical practice in Department of Defense beneficiaries

被引：0
|
作者：
Cota, J. M.
Bretzke, D. R.
Allerman, A. A.
Meade, D. J.
Trice, S.
机构：
[1] Univ Texas, Hlth Sci Ctr, San Antonio, TX USA
[2] Dept Defense Pharmaecon Ctr, Houston, TX USA
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)69007-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A154 / A154
页数：1
相关论文
共 50 条
  • [21] Comparison of Epoetin Alfa and Darbepoetin Alfa Dosing and Costs in an Inpatient Population with Myelodysplastic Syndromes.
    Lafeuille, Marie-Helene
    Vekeman, Francis
    Bailey, Robert A.
    McKenzie, R. Scott
    Lefebvre, Patrick
    BLOOD, 2008, 112 (11) : 469 - 469
  • [22] Comparison of darbepoetin alfa and epoetin alfa for radiotherapy(RT) or chemoradiotherapy(CT/RT)-induced anemia
    Sampe, P
    Vallejo, C
    Lopez-Carrizosa, C
    Rodriguez, A
    Suez, J
    Delgado, J
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S479 - S479
  • [23] First comparison of biosimilar epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-induced anaemia
    Lorenz, A.
    Heine, O.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S295 - S295
  • [24] Clinical outcomes associated with conversion from epoetin alfa to darbepoetin alfa in hospitalized hemodialysis patients
    Sarac, Erdal
    Chikyarappa, Anand
    Sabol, Brian
    Gemmel, David
    Globe, Denise
    Barlev, Arie
    Audhya, Paul
    AMERICAN JOURNAL OF NEPHROLOGY, 2006, 26 (06) : 571 - 578
  • [25] Regarding "randomized comparison of epoetin alfa and darbepoetin alfa in anemic patients with cancer receiving chemotherapy" - In Reply
    Waltzman, Roger
    ONCOLOGIST, 2006, 11 (05): : 536 - 537
  • [26] Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice
    Sasu, BJ
    Hartley, C
    Schultz, H
    McElroy, P
    Khaja, R
    Elliott, S
    Egrie, JC
    Browne, JK
    Begley, CG
    Molineux, G
    ACTA HAEMATOLOGICA, 2005, 113 (03) : 163 - 174
  • [27] Use and outcomes of epoetin alfa and darbepoetin alfa for anemic cancer patients in outpatient community practice settings.
    Fahrbach, KR
    Frame, D
    Sercus, B
    Schenkel, B
    BLOOD, 2005, 106 (11) : 485B - 486B
  • [28] A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia
    Schwartzberg, L
    Shiffman, R
    Tomita, D
    Stolshek, B
    Rossi, G
    Adamson, R
    CLINICAL THERAPEUTICS, 2003, 25 (11) : 2781 - 2796
  • [29] Impact of clinical/demographic characteristics and duration of clinical benefit on average weekly doses of darbepoetin alfa and epoetin alfa in oncology: Results from a claims analysis.
    Song, Xue
    Long, Stacey R.
    Kallich, Joel D.
    Marder, William D.
    BLOOD, 2006, 108 (11) : 482B - 482B
  • [30] Utilization trends of epoetin alfa and darbepoetin alfa in adult patients with cancer receiving chemotherapy in community practice settings.
    Coletti, T
    Howell, JB
    Todoroff, K
    Gregory, KL
    Fastenau, JM
    BLOOD, 2004, 104 (11) : 413B - 413B
12345